SCHEMBL5120867

SCHEMBL5120867

C#Cc1ccsc1-c1nc2cc(C)cc(C)n2c1NCc1ccccc1Cl.c1cc2cc-2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.36
TGFBR1 P36897 1/20 0.35
MAPK14 Q16539 1/20 0.35
TP53 P04637 3/20 0.34
RXFP1 Q9HBX9 1/20 0.34
GAA P10253 3/20 0.33
NR1H4 Q96RI1 2/20 0.33
HTR6 P50406 1/20 0.33
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
PKM P14618 1/20 0.33
PKLR P30613 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
POLB P06746 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 2/20 0.32
PDE5A O76074 1/20 0.32
ATM Q13315 1/20 0.32
HSD17B10 Q99714 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5127373 0.85 NR1H4 (0.38) MAPTTGFBR1MAPK14GAANR1H4
SCHEMBL5122919 0.84 NR1H4 (0.43) MAPTTGFBR1TP53RXFP1GAA
SCHEMBL5113157 0.82 NR1H4 (0.42) MAPTTP53GAANR1H4ALDH1A1
SCHEMBL5122906 0.80 NR1H4 (0.40) MAPTTP53RXFP1GAANR1H4
SCHEMBL5128014 0.80 NR1H4 (0.49) MAPTGAANR1H4ALDH1A1SMN1; SMN2
SCHEMBL5121823 0.78 PKLR (0.41) MAPTTP53GAAALDH1A1PKM
SCHEMBL5127697 0.77 MAPT (0.44) MAPTTP53GAANR1H4ALDH1A1
SCHEMBL5122914 0.76 NR1H4 (0.42) MAPTTGFBR1TP53RXFP1GAA
SCHEMBL5113704 0.75 PKM (0.42) MAPTTP53GAANR1H4ALDH1A1
SCHEMBL5122321 0.73 KDM4E (0.40) MAPTTP53GAANR1H4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791840-B1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH (DE) 2013-11-27 EP claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US claimed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US disclosed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS MAPT 707/4885TGFBR1 4567/4885MAPK14 2695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.